Cure the incurable
Redefining Cancer Therapy with First-in-Class Peptides, inspired by the power of human biology.
A breakthrough approach
PepKon has built a cutting-edge platform at the intersection of biology, chemistry, and artificial intelligence. This platform enables the in-house design, optimization, synthesis, and testing of new drug candidates.
Our mission is to address the limitations of current treatments by creating safer and more effective therapies.
In oncology, we’re committed to advancing breakthrough solutions for refractory and incurable cancers.
Targeting the TSP-1/CD47 pathway
PepKon is at the forefront of innovation with its proprietary pipeline of peptides designed to mimic the cell binding domain of the thrombospondin-1 to CD47.
These peptides were built on more than a decade of rigorous academic research.
Our primary ambition is to advance the lead candidate to first-in-human clinical trial, paving the way for a meaningful impact on patients' lives.
A dedicated and complementary team
PepKon is led by an accomplished management team with extensive expertise in research, pharmaceutical development, and entrepreneurship.
The company is further strengthened by a talented team of scientists and specialized consultants, supported by the insights of world-renowned researchers and physicians.
Together, this synergy of expertise drives transformative breakthroughs in cancer treatment.
Cancer care together
At PepKon, we advance the fight against cancer through strategic partnerships with top-tiers international institutions.
To ensure the highest quality in our work, we outsource in vivo preclinical studies and CMC-related activities to Clinical Research Organizations with proven expertise in their respective fields.
Backed by significant private and public fundings, we are empowered to push the boundaries of cancer research and innovation, together.